Key Takeaways:
- TQB3616 combination met its primary endpoint in a Phase II study at ASCO 2026.
- The CDK2/4/6 inhibitor targets patients resistant to prior CDK4/6i therapy.
- SBP shares fell 1% as Morgan Stanley cut its target price to HKD7.8.
Back
SBP Group's TQB3616 hits primary endpoint in Phase II ASCO study
SBP Group's TQB3616 combination regimen met its primary endpoint in a Phase II study of patients previously treated with CDK4/6 inhibitors, data at ASCO 2026 showed.
The results were announced by SBP's subsidiary Chia Tai Tianqing at the American Society of Clinical Oncology Annual Meeting, the company said. TQB3616 (brand name: Saitianxin) is a National Class 1 innovative drug classified as a CDK2/4/6 inhibitor, a next-generation therapy designed to target a broader range of cyclin-dependent kinases than first-generation CDK4/6 drugs such as Pfizer's Ibrance and Novartis's Kisqali.
The combination regimen demonstrated encouraging anti-tumor activity and controllable safety in patients who had developed resistance to prior CDK4/6 inhibitor therapy, according to the company. Specific efficacy and safety data from the trial were presented at the conference, though detailed response rates and adverse event rates have not yet been disclosed.
The data address a significant unmet need in breast cancer treatment. Patients who progress on CDK4/6 inhibitors — a standard first-line therapy for HR-positive, HER2-negative breast cancer, which represents about 70% of all breast cancer cases — currently have limited targeted options. TQB3616's dual inhibition of CDK2 and CDK4/6 is designed to overcome resistance mechanisms that emerge during prior therapy, potentially expanding the addressable patient population. Several drugmakers are developing next-generation CDK inhibitors targeting this resistance mechanism.
SBP shares fell 1% on the day, with short selling volume reaching HKD122.93 million, representing 22.5% of total turnover. Morgan Stanley maintained its Overweight rating on the stock while cutting its target price to HKD7.8, the bank said in a separate note.
The positive Phase II data could support advancement into later-stage trials. SBP Group did not disclose a timeline for a Phase III study. Investors will watch for additional data readouts at future medical conferences as the company seeks to establish TQB3616 as a treatment option for patients who have exhausted current CDK4/6 inhibitor therapy.
This article is for informational purposes only and does not constitute investment advice.
